Program
NKF-INS(G)
Also written as “NKF-INS(L)” and “NKF-INS(A)”.
Its studies are led by Xentria.
Furthest: phase 1, since Jul 1, 20243 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xentria | 30 open or running | phase 1since Jul 1, 2024 | Jul 1, 2024 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2024First study: phase 1 study in Healthy ParticipantsFirst studyNCT06492226 · 54 enrolled · South Africa
- Sep 30, 2024Phase 1 study in Healthy ParticipantsNCT06627478 · 114 enrolled · South Africa
- Sep 3, 2025Phase 1 study in Healthy Male Adult VolunteersNCT07165652 · 54 enrolled · South Africa
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07165652Healthy Male Adult Volunteers · South Africa | 1 | Completed | Mar 2, 2026 | 54 |
| NCT06627478Healthy Participants · South Africa | 1 | Completed | Jul 3, 2025 | 114 |
| NCT06492226Healthy Participants · South Africa | 1 | Completed | Oct 31, 2024 | 54 |
How it is read
Names in the registry
- “NKF-INS(G)”, 1 entry
- “NKF-INS(L)”, 1 entry
- “NKF-INS(A)”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.